Douglas Jacoby
Cardiovascular Disease · Philadelphia, PANPI 1477580371
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,978 of the $28,548 with a category attached, or 94.5%. 15 manufacturers reported payments, led by AstraZeneca at 55.7% of the total. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 48 payments — averaging $594.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$16K
- Novartis$5K
- Novo Nordisk$5K
- Regeneron Healthcare Solutions, Inc.$2K
- Amgen$146
- Heartflow, Inc.$103
- plus $185 from 9 others
Across 1 payment — averaging $8951.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amarin Pharma, Inc.$9K
What the payments were for
- Consulting fees$26,97895%
- Travel & lodging$6692%
- Food & beverage$8973%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $15,904 |
| Novartis | 5 | $5,402 |
| Novo Nordisk | 5 | $4,713 |
| Regeneron Healthcare Solutions, Inc. | 3 | $2,096 |
| Amgen | 4 | $146 |
| Heartflow, Inc. | 1 | $103 |
| Abiomed | 1 | $34 |
| Acarix USA Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Abbott | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Travere Therapeutics, Inc. | 5 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,548 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Praluent PenAlirocumab | 86 | $80,734 |
| Repatha SureclickEvolocumab | 97 | $80,037 |
| NexletolBempedoic Acid | 26 | $18,546 |
| VascepaIcosapent Ethyl | 24 | $18,440 |
| Ezetimibe | 154 | $6,133 |
| Carvedilol ErCarvedilol Phosphate | 11 | $3,575 |
| Rosuvastatin Calcium | 119 | $2,603 |
| Atorvastatin Calcium | 90 | $1,403 |
| Telmisartan | 43 | $1,292 |
| Metoprolol Succinate | 43 | $905 |
| Amlodipine Besylate | 52 | $430 |
| Losartan Potassium | 18 | $264 |
| Lisinopril | 16 | $157 |
| Metformin Hcl | 11 | $152 |
| Hydrochlorothiazide | 20 | $62 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.